ÁøÇàµÈ ¾Ç¼ºÁ¾¾ç ȯÀÚ¿¡¼ Recombinant Human Granulocyte Macrophage Colony-Stimulating Factor(LBD-005)ÀÇ Á¦ 1 »ó Àӻ󿬱¸
Phase I Study of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) in Patients with Advanced Malignancy
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÌÁ¤¾Ö
±èÇö¾Æ/ÀÌ°æÈÆ/¾ç¼ºÇö/Çã´ë¼®/¹æ¿µÁÖ/±èº´±¹/±è³ë°æ
KMID : 0360319930250040520
Abstract
A phase I study of yeast-derived recombinant human granulocyte-macrophage colony stimulating factor(rhGM-CSF) was undertaken in 27 patients with advanced malignancy. rhGM-CSF was administered once daily by subcutaneous(SC) injection(10 to
500¥ìg/§³/day)
for 10 days.
In present study, the maximum tolerated dose(MTD) was not reached up to the dose 500¥ìg/§³/day, but the dose-dependent increment of circulating granulocytes has been demonstrated and a plateau of hematologic effect was observed at rhGM-CSF dose
in
the
range of 150 to 350¥ìg/§³/day. The most common adverse drug events were fever(41%), bone pain/myalgia(26%), and skin rash(15%), but they were mild and well tolerated. Following a single SC injection at dosage levels of 50 to 500¥ìg/§³day,
detectable
serum levels occured within 30 minutes, peaked at 3.1¡¾3.1 hours(mean¡¾SD) and peak concentration were positively associated with dosage, followed by a rapid decrease occurring with a half life of 1.7¡¾0.6(mean¡¾SD).
Further studies will determine the impact on infection, morbidity, and mortality in patients who receive intensive anti-cancer chemotherapy. The optimal dose level of rhGM-CSF to be used in phase¥±study is suggested to be in the range of 150 to
350¥ìg/§³/day.
Å°¿öµå
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸